New diabetes drug SHR-3167 takes on insulin in Head-to-Head trial
NCT ID NCT06688123
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called SHR-3167 against a standard insulin (insulin glargine) for people with type 2 diabetes. About 275 adults who are not on insulin yet, but take metformin (alone or with another diabetes drug), will receive either SHR-3167 or insulin glargine. The main goal is to see which treatment better lowers blood sugar levels (HbA1c) over 20 weeks, while also checking for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, 210029, China
-
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, 200233, China